
Anavex Life Sciences Corp. (NASDAQ:AVXL) announced the latest findings on Thursday for blarcamesine, an oral small molecule that could potentially treat early Alzheimer’s disease.
The data were presented at the 2025 Alzheimer’s Association International Conference.